CTOs on the Move

Adfinitas Health

www.adfinitashealth.com

 
Adfinitas Health (formerly MDICS) is Marylands largest private hospitalist group of physicians, nurse practitioners and physician assistants, dedicated to providing comprehensive, cost-effective, high-quality medical care to patients in hospitals, ski...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Butterfield's Pharmacy and Medical Supplies

Butterfield's Pharmacy and Medical Supplies is a Fort Pierce, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avanti Therapeutics

Avanti Therapeutics is a Clarksburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medaus Pharmacy

Medaus Pharmacy is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MMS Holdings

MMS is an award-winning, global clinical research organization (CRO) that supports leading pharmaceutical and biotech companies as well as many smaller enterprises across our spectrum of services. Having completed more than 50 submissions for drug approval over the last 5 years, we remain a top choice for sponsors who are looking for innovation and demand high quality from their CRO partners. Senior leadership at MMS has more than two decades of hands-on drug development experience which helps support program-level strategy and execution of projects across multiple therapeutic areas. Continual staff training, innovative recruitment and motivating career opportunities help MMS retain the best talent and develop a strong, client-focused workforce across all global locations. Our mission is to deliver high-quality services, rooted in good science and decades of regulatory experience, that will assist our clients in developing and marketing life-changing therapies, thereby positively affecting patients` lives worldwide.

Radionetics

Radionetics Oncology is a pharmaceutical company focused on the discovery and development of novel radiotherapeutics for the treatment of a wide range of oncology indications. The company`s platform technology uses nonpeptide, small molecule targeting to deliver therapeutic radioisotopes to a broad range of cancers by binding selectively to peptide receptors that are selectively expressed on these tumors. This nonpeptide technology addresses many of the significant challenges currently facing peptide and protein targeted radiotherapeutics, particularly in the realm of optimizing drug-like characteristics and manufacturing. The company is rapidly advancing a pipeline of drug candidates to treat a broad range of cancers and is conducting additional drug discovery efforts to identify drug candidates for additional receptor targets in collaboration with Crinetics Pharmaceuticals.